Zhao X F, Mao X F, Wan D M, Liu W
Department of Hematology and Oncology, Children's Hospital of Zhengzhou, Zhengzhou, China.
Department of Internal Medicine, The No.Three People's Hospital of Henan, Henan, China.
Transplant Proc. 2014 Jun;46(5):1531-5. doi: 10.1016/j.transproceed.2014.02.023.
We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies.
A total of 45 patients with hematologic malignancies were treated using stem cell transplantation between March 2007 and June 2012. All the patients received a modified BU/CY conditioning regimen before transplantation. The outcomes of the patients were followed up including mortality, survival, relapse, and complications.
The median of follow-up duration was 527 days. All the patients who received modified BU/CY conditioning regimen achieved hematopoietic recovery successfully. Among the patients, 24 were survived without complications, 5 had relapsed hematologic malignancies, and 16 died. The median time to leucocyte engraftment was 14 days and to platelet engraftment was 12 days. Acute graft-versus-host disease (aGVHD; grades I-IV) occurred in 15 patients (30%). The cumulative incidence of grades I aGVHD was 22.2% (10 patients), grades II was 6.7% (3 patients), and grades III-IV was 4.4% (2 patients). Among 40 appreciable patients, 8 (20%) developed chronic GVHD. The incidence rate of hemorrhagic cystitis and veno-occlusive disease were 15.5% and 2.2%, respectively.
The modified BU/CY conditioning regimen for allo-HSCT is effective and safe for the treatment of hematologic malignancies.
我们旨在评估改良白消安和环磷酰胺（BU/CY）预处理方案在异基因造血干细胞移植（allo-HSCT）治疗血液系统恶性肿瘤中的临床疗效。
2007年3月至2012年6月期间，共有45例血液系统恶性肿瘤患者接受了干细胞移植治疗。所有患者在移植前均接受了改良的BU/CY预处理方案。对患者的结局进行随访，包括死亡率、生存率、复发率和并发症。
随访时间中位数为527天。所有接受改良BU/CY预处理方案的患者均成功实现造血恢复。其中，24例患者存活且无并发症，5例患者血液系统恶性肿瘤复发，16例患者死亡。白细胞植入的中位时间为14天，血小板植入的中位时间为12天。15例患者（30%）发生了急性移植物抗宿主病（aGVHD；I-IV级）。I级aGVHD的累积发生率为22.2%（10例患者），II级为6.7%（3例患者），III-IV级为4.4%（2例患者）。在40例可评估的患者中，8例（20%）发生了慢性GVHD。出血性膀胱炎和静脉闭塞性疾病的发生率分别为15.5%和2.2%。
改良的BU/CY预处理方案用于allo-HSCT治疗血液系统恶性肿瘤有效且安全。
